Moreover, given the immune landscape, we propose that VAV1 is the key molecule involved in ILBRS-relevant survival mechanisms, indicating its potential as an immune therapeutic target for PCa patients with poor prognoses. The gene discussed is VAV1; the disease is posterior cortical atrophy.